Results 131 to 140 of about 11,372 (280)

Treatment of Aspergillosis. [PDF]

open access: yes, 2018
Infections caused by Aspergillus spp. remain associated with high morbidity and mortality. While mold-active antifungal prophylaxis has led to a decrease of occurrence of invasive aspergillosis (IA) in those patients most at risk for infection ...
Hoenigl, Martin, Jenks, Jeffrey D
core   +1 more source

Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis

open access: yesInternational Journal of Infectious Diseases, 2019
Objective: To describe the pharmacokinetic (PK) profile of anidulafungin and to evaluate its concentration in the peritoneal fluid (PF) of patients suspected of suffering from peritoneal infection undergoing abdominal surgery, in order to ensure that ...
D.V. Pérez Civantos   +5 more
doaj  

Anidulafungin increases the antibacterial activity of tigecycline in polymicrobial Candida albicans/Staphylococcus aureus biofilms on intraperitoneally implanted foreign bodies

open access: yesJournal of Antimicrobial Chemotherapy, 2018
Objectives We aimed to establish a novel murine intra-abdominal foreign body infection model to study the activity of anidulafungin and tigecycline against dual species Candida albicans/Staphylococcus aureus biofilms.
Ona Rogiers   +7 more
semanticscholar   +1 more source

Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America [PDF]

open access: yes, 2017
Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America.
Andes, David   +13 more
core  

Emerging Threats in Antifungal-Resistant Fungal Pathogens. [PDF]

open access: yes, 2016
The use of antifungal drugs in the therapy of fungal diseases can lead to the development of antifungal resistance. Resistance has been described for virtually all antifungal agents in diverse pathogens, including Candida and Aspergillus species.
Sanglard, D.
core   +2 more sources

Disk Diffusion-Based Methods for Determining Candida parapsilosis Susceptibility to Anidulafungin [PDF]

open access: green, 2003
Zekaver Odabaşı   +4 more
openalex   +1 more source

A Randomized, Double-Blind Trial of Anidulafungin versus Fluconazole for the Treatment of Esophageal Candidiasis [PDF]

open access: bronze, 2004
David S. Krause   +7 more
openalex   +1 more source

Candida infections, causes, targets and resistance mechanisms. Traditional and alternative antifungal agents [PDF]

open access: yes, 2013
The genus Candida includes about 200 different species, but only a few species are human opportunistic pathogens and cause infections when the host becomes debilitated or immunocompromised. Candida infections can be superficial or invasive.
Leonardi, Darío   +1 more
core   +3 more sources

In Vitro Activity of Anidulafungin against Selected Clinically Important Mold Isolates [PDF]

open access: green, 2004
Zekaver Odabaşı   +4 more
openalex   +1 more source

Population Pharmacokinetics of Anidulafungin in Critically Ill Patients

open access: yesAntimicrobial Agents and Chemotherapy, 2019
A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]).
S. Luque   +11 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy